Compare AbCellera Biologics Inc (ABCL) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.99B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.42. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | TLT | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $92.06 |
52-Week Low | $2.78 | $82.05 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
